we are already facing multi drug resistant bacteria and people are dying everyday. why there is little research happening on this field all over the world ovbsly leaving Russia, poland etc. Why only they see the potential of this type of therapy?
ContraFect's (Yonkers, NY) bacteriophage-derived lysin CF-301 for the treatment of Staphylococcus aureus bacteremia has already completed a Phase 1 clinical trial.